Health Care • Biotechnology: Pharmaceutical Preparations
$10.15 ▼ -0.22
(-2.17%)
MKT CAP: $2.05B • VOL: 8.36M
52W L $1 52W H $16
ROARABLE / RQD
D- • 35/100
PIOTROSKI
2 / 9
SLS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$28.3M | -$31.5M | -$37.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$26.9M | -$30.9M | -$37.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$28.4M | -$35.4M | -$31.4M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$28.4M | -$35.4M | -$31.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $71.8M | $13.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $70.9M | $9.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SLS.